TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 31888589

Group type: EXPERIMENTAL
Intervention: Gain-framed incentives
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Loss-framed incentives
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Lottery-based incentives
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Public settings with incentives
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Low perceived prize values
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Intrinsic motivation to test
Number of subjects: 60
Study: 28708863

Group type: EXPERIMENTAL
Intervention: IL-2 administration with therapeutic vaccination (ALVACHIV/Lipo-6T)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: IL-2 administration
Number of subjects: 0
Study: 25345664

Group type: EXPERIMENTAL
Intervention: Intentional harm scenario
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Unintentional harm scenario
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Paranoia assessment
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Anxiety assessment
Number of subjects: 300
Study: 23922114

Group type: EXPERIMENTAL
Intervention: Panobinostat 40 mg thrice weekly (initially), then reduced to 20 mg thrice weekly after nine patients due to safety concerns.
Number of subjects: 47
Study: 20739577

Group type: EXPERIMENTAL
Intervention: Story-sharing group in their own language
Number of subjects: 157

Group type: COMPARATOR
Intervention: Usual care self-management education (control)
Number of subjects: 157
Study: 18501096

Group type: EXPERIMENTAL
Intervention: Paclitaxel and carboplatin with bevacizumab
Number of subjects: 260

Group type: COMPARATOR
Intervention: Paclitaxel and carboplatin without bevacizumab (control group)
Number of subjects: 260
Study: 17134516

Group type: EXPERIMENTAL
Intervention: Stanford Arthritis Self-Management Program (ASMP) and an arthritis self-management book
Number of subjects: 600

Group type: COMPARATOR
Intervention: Control group (arthritis self-management book only)
Number of subjects: 600

Group type: EXPERIMENTAL
Intervention: Stanford ASMP
Number of subjects: 600
Study: 12796155

Group type: EXPERIMENTAL
Intervention: Salmeterol, 50 micro g bid
Number of subjects: 2853

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2853
Study: 11007224

Group type: EXPERIMENTAL
Intervention: Single rapid bolus of meperidine and midazolam
Number of subjects: 101

Group type: COMPARATOR
Intervention: Titration of doses every 3 min until predefined levels of somnolence were achieved
Number of subjects: 101
Study: 8985524

Group type: EXPERIMENTAL
Intervention: Mefloquine (25 mg/kg total, divided into 15 mg/kg initially and 10 mg/kg after 12 hours)
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: Mefloquine combined with an artemisinin derivative
Number of subjects: 500
Study: 1476911

Group type: EXPERIMENTAL
Intervention: Nifedipine (calcium blocker)
Number of subjects: 144

Group type: COMPARATOR
Intervention: Dipyridamole (control)
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: Nifedipine
Number of subjects: 144
Study: 6731327

Group type: EXPERIMENTAL
Intervention: Metoprolol
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 31326630

Group type: EXPERIMENTAL
Intervention: Anterior cervical discectomy with arthroplasty
Number of subjects: 253

Group type: EXPERIMENTAL
Intervention: Anterior cervical discectomy with intervertebral cage
Number of subjects: 253

Group type: EXPERIMENTAL
Intervention: Anterior cervical discectomy without intervertebral cage
Number of subjects: 253
Study: 29187594

Group type: EXPERIMENTAL
Intervention: High plasma urate (100 µmol/L increase)
Number of subjects: 114979

Group type: EXPERIMENTAL
Intervention: Genetically determined high plasma urate (100 µmol/L increase)
Number of subjects: 114979

Group type: EXPERIMENTAL
Intervention: High plasma urate
Number of subjects: 114979
Study: 26891879

Group type: EXPERIMENTAL
Intervention: Risperidone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Aripiprazole
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Novel glutamate-modulating agents
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 25490802

Group type: EXPERIMENTAL
Intervention: Likelihood Alarm Systems (LASs)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Binary Alarm Systems (BASs)
Number of subjects: 0
Study: 22527829

Group type: EXPERIMENTAL
Intervention: Vitamin E (total dose 2160 mg i.v.) + 0.45% saline (1 mL/kg/h over 24 h)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (total dose 4800 mg p.o.) + 0.45% saline (1 mL/kg/h over 24 h)
Number of subjects: 30

Group type: COMPARATOR
Intervention: 0.45% saline alone
Number of subjects: 30
Study: 20484838

Group type: EXPERIMENTAL
Intervention: Beverages with apple polyphenols (600 mg)
Number of subjects: 124

Group type: COMPARATOR
Intervention: Beverages without apple polyphenols (placebo)
Number of subjects: 124
Study: 17115178

Group type: EXPERIMENTAL
Intervention: Active recovery (IE(A), 50% of MAV)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Passive recovery (IE(P))
Number of subjects: 8
Study: 16140974

Group type: EXPERIMENTAL
Intervention: Adjuvant tamoxifen for 2 years
Number of subjects: 500

Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 500
Study: 12097660

Group type: EXPERIMENTAL
Intervention: Iron supplementation (100 mg Fe/d as ferrous sulfate) for 6 weeks
Number of subjects: 23

Group type: COMPARATOR
Intervention: Zinc supplementation (22 mg Zn/d as zinc gluconate) for 6 weeks
Number of subjects: 23
Study: 10081531

Group type: EXPERIMENTAL
Intervention: Ketorolac 0.9 mg kg‐1 i.v.
Number of subjects: 52

Group type: COMPARATOR
Intervention: Pethidine 0.5 mg kg‐1 i.v.
Number of subjects: 52
Study: 7593724

Group type: EXPERIMENTAL
Intervention: Moclobemide once daily (OD)
Number of subjects: 189

Group type: EXPERIMENTAL
Intervention: Moclobemide three times daily (TDS)
Number of subjects: 189

Group type: COMPARATOR
Intervention: Placebo (used for double-blind control)
Number of subjects: 189
Study: 2407336

Group type: EXPERIMENTAL
Intervention: IF radiotherapy + MOPP chemotherapy
Number of subjects: 228

Group type: COMPARATOR
Intervention: IF radiotherapy alone
Number of subjects: 228

Group type: COMPARATOR
Intervention: EF radiotherapy
Number of subjects: 228

Group type: EXPERIMENTAL
Intervention: IF radiotherapy + MOPP chemotherapy (CCSG and CALGB)
Number of subjects: 228
Study: 6893563

Group type: EXPERIMENTAL
Intervention: Carbimazole
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 31956660

Group type: EXPERIMENTAL
Intervention: Cod-liver oil
Number of subjects: 550

Group type: COMPARATOR
Intervention: Control (placebo, mineral oil)
Number of subjects: 550
Study: 30369321

Group type: EXPERIMENTAL
Intervention: Standard care for OSA diagnosis and treatment
Number of subjects: 252

Group type: EXPERIMENTAL
Intervention: Enhanced care for OSA diagnosis and treatment
Number of subjects: 252

Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 252

Group type: EXPERIMENTAL
Intervention: Continuous positive airway pressure use among patients with OSA
Number of subjects: 252

Group type: EXPERIMENTAL
Intervention: Intervention patients with best neurological symptom severity (National Institutes of Health Stroke Scale score, 0-1)
Number of subjects: 252
Study: 26975818

Group type: EXPERIMENTAL
Intervention: CVVH
Number of subjects: 36

Group type: COMPARATOR
Intervention: Conventional treatment
Number of subjects: 36
Study: 24909563

Group type: EXPERIMENTAL
Intervention: Orthosis/stretch combinations
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Conservative treatments (1 or more)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Surgery for CTS
Number of subjects: 96
Study: 22454332

Group type: EXPERIMENTAL
Intervention: Simon task
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Stimulus-Response Compatibility (SRC) task
Number of subjects: 0
Study: 19461562

Group type: EXPERIMENTAL
Intervention: 12.5 mg/mL morphine with 0.2% ropivacaine
Number of subjects: 40

Group type: COMPARATOR
Intervention: 25 mg/mL morphine with 0.2% ropivacaine
Number of subjects: 40
Study: 17617283

Group type: COMPARATOR
Intervention: Moxonidine 0.2 mg once daily (M0.2)
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Moxonidine 0.2 mg BID (M0.4)
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Moxonidine 0.2 mg plus Irbesartan 150 mg (M0.2+1)
Number of subjects: 99
Study: 15165654

Group type: EXPERIMENTAL
Intervention: Skills training intervention (manual plus five weekly group-based sessions)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Skills training intervention
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control condition (one-page leaflet)
Number of subjects: 60
Study: 12117747

Group type: EXPERIMENTAL
Intervention: Dexrazoxane (500 mg/m2)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 10088770

Group type: EXPERIMENTAL
Intervention: Intraarticular corticosteroids (3.75 mg of cortivazol in 1.5 ml)
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Joint lavage and intraarticular corticosteroid
Number of subjects: 98

Group type: COMPARATOR
Intervention: Intraarticular placebo (1.5 ml of 0.9% normal saline)
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Joint lavage and intraarticular placebo
Number of subjects: 98
Study: 7491940

Group type: EXPERIMENTAL
Intervention: 56 mg arginine.kg‐1.day‐1 for 6 days
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: 561 mg arginine.kg‐1.day‐1 for 6 days
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Arginine supplementation
Number of subjects: 5
Study: 2110560

Group type: EXPERIMENTAL
Intervention: Fluvoxamine
Number of subjects: 54

Group type: COMPARATOR
Intervention: Imipramine
Number of subjects: 54

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 54
Study: 341733

Group type: EXPERIMENTAL
Intervention: Metronidazole-neomycin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Erythromycin-neomycin
Number of subjects: 0
Study: 30620948

Group type: EXPERIMENTAL
Intervention: Cap‐assisted esophagogastroduodenoscopy (CA‐EGD)
Number of subjects: 171

Group type: COMPARATOR
Intervention: Standard duodenoscopy
Number of subjects: 171

Group type: EXPERIMENTAL
Intervention: CA‐EGD
Number of subjects: 171
Study: 28244271

Group type: EXPERIMENTAL
Intervention: Parent-delivered intervention promoting first relationships (PFR), n=19
Number of subjects: 33

Group type: COMPARATOR
Intervention: Ongoing assessment without intervention, n=14
Number of subjects: 33
Study: 26390746

Group type: EXPERIMENTAL
Intervention: i-gel
Number of subjects: 163

Group type: COMPARATOR
Intervention: LMA ProSeal
Number of subjects: 163
Study: 23365148

Group type: EXPERIMENTAL
Intervention: Ayurvedic formulations (SGCG and SGC)
Number of subjects: 440

Group type: COMPARATOR
Intervention: Glucosamine (2 g daily)
Number of subjects: 440

Group type: COMPARATOR
Intervention: Celecoxib (200 mg daily)
Number of subjects: 440
Study: 22168295

Group type: EXPERIMENTAL
Intervention: Culturally tailored care management intervention
Number of subjects: 30

Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 30
Study: 19127197

Group type: EXPERIMENTAL
Intervention: Exercise training (EG)
Number of subjects: 65
Study: 16912480

Group type: EXPERIMENTAL
Intervention: High-frequency cranial electrostimulation (CES) for 30 min a day, during 6 weeks
Number of subjects: 20

Group type: COMPARATOR
Intervention: Sham stimulation (control) for 30 min a day, during 6 weeks
Number of subjects: 20
Study: 10621518

Group type: EXPERIMENTAL
Intervention: Self-help programs
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Group-based programs
Number of subjects: 41

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 41
Study: 8751544

Group type: EXPERIMENTAL
Intervention: Paclitaxel (135 or 175 mg/m2) over 3 hr followed by cisplatin (75 mg/m2)
Number of subjects: 38
Study: 1910100

Group type: EXPERIMENTAL
Intervention: Immediate postoperative nasojejunal feeding with full strength Osmolite solution for 56 hours (n = 16)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Routine postoperative hypocaloric fluids and gradual reintroduction of diet (n = 16)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Immediate postoperative nasojejunal feeding
Number of subjects: 32

Group type: COMPARATOR
Intervention: Routine postoperative hypocaloric fluids
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Immediate postoperative nasojejunal feeding and Routine postoperative hypocaloric fluids
Number of subjects: 32
Study: 6883850

Group type: EXPERIMENTAL
Intervention: Cold application
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Heat application
Number of subjects: 36
Study: 29384426

Group type: EXPERIMENTAL
Intervention: Intervention group (n = 27)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Control group (n = 28)
Number of subjects: 55
Study: 29395424

Group type: EXPERIMENTAL
Intervention: Intramuscular injections of allogeneic MSCs
Number of subjects: 32

Group type: COMPARATOR
Intervention: Autogenous concentrated bone marrow aspirate
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Clinical limb perfusion assessment
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: All-cause mortality, need for amputation revision, gangrene incidence
Number of subjects: 32
Study: 25236322

Group type: EXPERIMENTAL
Intervention: Clindamycin phosphate
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Benzoyl peroxide
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Combination of clindamycin phosphate plus benzoyl peroxide
Number of subjects: 240

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 240
Study: 24451290

Group type: EXPERIMENTAL
Intervention: Dual-chamber pacing (DDDR)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Single-lead atrial pacing (AAIR)
Number of subjects: 0
Study: 22705129

Group type: EXPERIMENTAL
Intervention: Computed Tomography Angiography (CTA)
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: T2-weighted MRI
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Angiography (MRA)
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging (MRI)
Number of subjects: 125
Study: 21290834

Group type: EXPERIMENTAL
Intervention: Pricking blood along meridians combined with electroacupuncture
Number of subjects: 100

Group type: COMPARATOR
Intervention: Electroacupuncture (control group)
Number of subjects: 100
Study: 17141470

Group type: EXPERIMENTAL
Intervention: Intraoral vertical ramus osteotomy (IVRO)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Obwegeser method (Ob)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Obwegeser-Dal Pont method (ODP)
Number of subjects: 30
Study: 16297756

Group type: EXPERIMENTAL
Intervention: Propofol infusion with a preset target concentration of 2.5 microg/mL until sedation level 3 was achieved.
Number of subjects: 150

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 150
Study: 12905798

Group type: EXPERIMENTAL
Intervention: Ambulatory pH monitoring in elderly patients with GERD
Number of subjects: 72

Group type: COMPARATOR
Intervention: Control group (patients less than 65 years old)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Elderly patients with GERD
Number of subjects: 72
Study: 9704200

Group type: EXPERIMENTAL
Intervention: Phenylbutazone 10 mg/kg intramuscularly
Number of subjects: 29

Group type: COMPARATOR
Intervention: Control injection (vehicle-containing local anaesthetic)
Number of subjects: 29
Study: 8539544

Group type: EXPERIMENTAL
Intervention: Sulfamethoxazole-trimethoprim (SMX-TMP) 400/80 mg b.i.d.
Number of subjects: 94

Group type: COMPARATOR
Intervention: Aerosolized pentamidine (AP) 60 mg every 2nd week
Number of subjects: 94
Study: 31900813

Group type: EXPERIMENTAL
Intervention: Medication providing a 'cure' with flu-like symptoms
Number of subjects: 454

Group type: EXPERIMENTAL
Intervention: Medication providing a 'remission' labeled as 'cure' with flu-like symptoms
Number of subjects: 454

Group type: COMPARATOR
Intervention: Medication providing a 'remission' without labeling as 'cure'
Number of subjects: 454
Study: 31687955

Group type: EXPERIMENTAL
Intervention: Nitroglycerin (8-10 μg/kg*min)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Control group (no nitroglycerin)
Number of subjects: 72
Study: 27559692

Group type: EXPERIMENTAL
Intervention: E-cigarette administration
Number of subjects: 9

Group type: COMPARATOR
Intervention: Tobacco cigarette administration
Number of subjects: 9
Study: 26046707

Group type: EXPERIMENTAL
Intervention: iDesign
Number of subjects: 30

Group type: COMPARATOR
Intervention: WaveScan
Number of subjects: 30
Study: 23482083

Group type: EXPERIMENTAL
Intervention: 0.25-0.8 Hz pulsed RF EMF exposure
Number of subjects: 16

Group type: COMPARATOR
Intervention: Sham exposure
Number of subjects: 16
Study: 20848538

Group type: EXPERIMENTAL
Intervention: Endoscopic assessment
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: CDAI scores
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Mean CRP and ESR values
Number of subjects: 24
Study: 19194270

Group type: EXPERIMENTAL
Intervention: IL-2 therapy
Number of subjects: 92

Group type: COMPARATOR
Intervention: Antiretroviral therapy alone
Number of subjects: 92
Study: 17533020

Group type: EXPERIMENTAL
Intervention: Atorvastatin, 40 mg/d for 6 weeks
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Gemfibrozil, 600 mg twice daily for 6 weeks
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 15576517

Group type: EXPERIMENTAL
Intervention: Valdecoxib 40 mg
Number of subjects: 51

Group type: COMPARATOR
Intervention: Oxycodone 10 mg with acetaminophen 650 mg
Number of subjects: 51
Study: 11344672

Group type: EXPERIMENTAL
Intervention: PEEP at 0.2 kPa
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: PEEP at 0.3 kPa
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: PEEP at 0.4 kPa
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: PEEP levels (0.2, 0.3, 0.4 kPa)
Number of subjects: 20
Study: 9741224

Group type: EXPERIMENTAL
Intervention: Recombinant human erythropoietin (EPO) 150 units/kg per day
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 8306408

Group type: EXPERIMENTAL
Intervention: AdVP (doxorubicin, vincristine, and prednisolone)
Number of subjects: 198

Group type: EXPERIMENTAL
Intervention: L-AdVP (doxorubicin, vincristine, prednisolone, and L-asparaginase)
Number of subjects: 198

Group type: COMPARATOR
Intervention: L-AdVP
Number of subjects: 198
Study: 2647291

Group type: EXPERIMENTAL
Intervention: Whole body hyperthermia (WBH) at 40.5 degrees C for 75 min
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Human lymphoblastoid interferon (IFN) administered i.m. at doses of 1 x 10(6) units/m2, 3 x 10(6) units/m2, and 10 x 10(6) units/m2
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Combination of WBH and human lymphoblastoid IFN
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Maintenance therapy with IFN
Number of subjects: 17
Study: 52367

Group type: EXPERIMENTAL
Intervention: Intensive chemotherapy (quintuple drug regimen: mechloretamine, adriamycin, bleomycin, vincristine, and prednisone)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intensive chemotherapy (quintuple drug regimen)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combination chemotherapy followed by involved field irradiation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Cyclophosphamide, vincristine, and prednisone (CVP)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Radiotherapy plus CVP
Number of subjects: 0
Study: 29886347

Group type: EXPERIMENTAL
Intervention: Nurse-led group treatment based on CBT-I (n=90)
Number of subjects: 165

Group type: COMPARATOR
Intervention: Treatment as usual (n=75)
Number of subjects: 165
Study: 28756415

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioural therapy (CBT)
Number of subjects: 211

Group type: EXPERIMENTAL
Intervention: Return-to-work intervention (RTW-I)
Number of subjects: 211

Group type: EXPERIMENTAL
Intervention: Combined CBT and RTW-I (COMBO)
Number of subjects: 211

Group type: COMPARATOR
Intervention: All treatments (CBT, RTW-I, COMBO)
Number of subjects: 211
Study: 25135867

Group type: EXPERIMENTAL
Intervention: Statin users
Number of subjects: 543

Group type: COMPARATOR
Intervention: Non-users
Number of subjects: 543
Study: 23914908

Group type: EXPERIMENTAL
Intervention: Brief Motivational Interviewing (MI)
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: Health Education (HE)
Number of subjects: 400
Study: 21654341

Group type: EXPERIMENTAL
Intervention: Assisted countermovement jump training (n = 9)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Resisted countermovement jump training (n = 11)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Free countermovement jump training (n = 8)
Number of subjects: 28
Study: 18486782

Group type: EXPERIMENTAL
Intervention: HemCon Dental Dressing (HDD)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (standard treatment)
Number of subjects: 0
Study: 17000189

Group type: EXPERIMENTAL
Intervention: Plant stanol-enriched margarine with lipid-lowering dietary intervention
Number of subjects: 20

Group type: COMPARATOR
Intervention: Standard care (margarine without plant stanols)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Both groups (plant stanol and control)
Number of subjects: 20
Study: 14558436

Group type: EXPERIMENTAL
Intervention: 10 mg manidipine dihydrochloride
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: 30 mg delapril hydrochloride
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Simultaneous administration of 10 mg manidipine and 30 mg delapril
Number of subjects: 18
Study: 10929148

Group type: EXPERIMENTAL
Intervention: Amodiaquine
Number of subjects: 246

Group type: EXPERIMENTAL
Intervention: Sulfadoxine/pyrimethamine
Number of subjects: 246

Group type: EXPERIMENTAL
Intervention: Amodiaquine and sulfadoxine/pyrimethamine
Number of subjects: 246
Study: 8811399

Group type: EXPERIMENTAL
Intervention: High expressed emotion (EE)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Low expressed emotion (EE)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Emotional exhaustion, depersonalisation, and GHQ levels
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Personal accomplishment and job satisfaction
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: High EE interviews
Number of subjects: 10
Study: 1568861

Group type: EXPERIMENTAL
Intervention: Naltrexone
Number of subjects: 31

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study: 3880714

Group type: EXPERIMENTAL
Intervention: 750 mg penicillamine
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: 250 mg penicillamine
Number of subjects: 53
Study: 31291305

Group type: EXPERIMENTAL
Intervention: Zinc Methionine (ZM)
Number of subjects: 1482

Group type: EXPERIMENTAL
Intervention: Zinc Sulfate (ZS)
Number of subjects: 1482

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1482